NBIX
Neurocrine Biosciences, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Market Cap: 13.2 Billion
Primary Exchange: NASDAQ
Website: http://www.neurocrine.com/
Shares Outstanding: 99.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.43279353194204995
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1106 trading days
From: 2020-07-15 To: 2024-01-04
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
via: PR Newswire at 2019-06-11 12:01:00:000
SAN DIEGO , June 11, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatme… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|